A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)
Phase 3
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- JPRN-jRCT2080221281
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Child-Pugh score of < 9 (Child-Pugh A or B [B7 or B8])
-BCLC stage C or BCLC B not amenable to locorrectional therapy or refractory to locoregional therapy.
-Diagnosis of HCC (excluding fibrolamellar carcinoma)
-The patient has received sorafenib as the most recent systemic therapeutic intervention.
-Adequate Organ Function
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method